Pancreas Cancer Clinical Trials

94 recruitingLast updated: June 17, 2026

There are 94 actively recruiting pancreas cancer clinical trials across 25 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Pancreas Cancer Trials at a Glance

94 actively recruiting trials for pancreas cancer are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 1 with 27 trials, with the heaviest enrollment activity in New York, Boston, and Houston. Lead sponsors running pancreas cancer studies include Minia University, Chongqing Precision Biotech Co., Ltd, and Second Affiliated Hospital of Guangzhou Medical University.

Browse pancreas cancer trials by phase

Treatments under study

About Pancreas Cancer Clinical Trials

Looking for clinical trials for Pancreas Cancer? There are currently 92 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreas Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreas Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 94 trials

Recruiting

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

CholangiocarcinomaPancreas CancerColorectal Neoplasms+2 more
National Cancer Institute (NCI)1,800 enrolled1 locationNCT01915225
Recruiting
Phase 1Phase 2

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

Pancreatic CancerPancreas Cancer
University of Virginia23 enrolled1 locationNCT06479239
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Breast CancerColorectal, CancerProstate Cancer+9 more
University Health Network, Toronto500 enrolled3 locationsNCT05403177
Recruiting
Phase 1

Autologous CAR-T Cells Targeting B7-H3 in PDAC

Pancreas CancerRelapseResistant Cancer
UNC Lineberger Comprehensive Cancer Center27 enrolled1 locationNCT06158139
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting

A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

Pancreatic CancerPancreas Cancer
Memorial Sloan Kettering Cancer Center79 enrolled7 locationsNCT07612046
Recruiting
Not Applicable

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

Liver CancerEsophageal CancerColon Cancer+7 more
Case Comprehensive Cancer Center200 enrolled1 locationNCT06263088
Recruiting
Phase 3

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

Pancreas CancerOligometastatic
M.D. Anderson Cancer Center80 enrolled3 locationsNCT06593431
Recruiting
Not Applicable

Promoting CT Engagement for Pancreatic Cancer With App

Pancreas Cancer
UNC Lineberger Comprehensive Cancer Center26 enrolled2 locationsNCT06252545
Recruiting
Not Applicable

Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer

Breast CancerColon CancerPancreas Cancer+3 more
Gustave Roussy, Cancer Campus, Grand Paris170 enrolled3 locationsNCT07436312
Recruiting
Not Applicable

Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence

Pancreas Cancer
Medical College of Wisconsin40 enrolled1 locationNCT06228599
Recruiting
Phase 2

Axelopran for Advanced Cancer in Patients Receiving Opioids

Breast CancerProstate CancerLung Cancer+1 more
HealthPartners Institute34 enrolled2 locationsNCT07354919
Recruiting
Phase 1Phase 2

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Locally Advanced Pancreatic AdenocarcinomaLocally Advanced Pancreas CancerLocally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma36 enrolled4 locationsNCT07157033
Recruiting
Phase 2

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Pancreas Cancer
Shandong Cancer Hospital and Institute25 enrolled1 locationNCT06050317
Recruiting
Not Applicable

Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening

Pancreatic Ductal AdenocarcinomaPancreas CancerHereditary Diseases+1 more
Lipidica, a.s.419 enrolled16 locationsNCT06549725
Recruiting

Pancreatic Cancer Early Detection Consortium

Pancreatic Ductal AdenocarcinomaPancreas CancerGenetic Predisposition+1 more
Arbor Research Collaborative for Health20,000 enrolled60 locationsNCT04970056
Recruiting

Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma

Pancreas Cancer
Institut Bergonié50 enrolled1 locationNCT06705335
Recruiting
Phase 2

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Pancreatic CancerPancreas CancerPancreatic Adenocarcinoma+1 more
Washington University School of Medicine36 enrolled1 locationNCT07126158
Recruiting
Phase 1

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Breast CancerOvarian CancerProstate Cancer+6 more
Nammi Therapeutics Inc100 enrolled10 locationsNCT06582017